ILK-IN-1

• CAT Number: I001269
• CAS Number: 1333146-24-9
• Molecular Formula: C30H30F3N5O
• Molecular Weight: 533.59
• Purity: ≥95%
• Target: Integrin
• Solubility: 10 mM in DMSO
• Storage: -20°C
• IC50: 0.6 μM
• IUPAC Name: N-methyl-3-[1-(4-piperazin-1-ylphenyl)-5-[4-[4-(trifluoromethyl)phenyl]phenyl]pyrazol-3-yl]propanamide
• InChI: InChI=1S/C30H30F3N5O/c1-34-29(39)15-10-25-20-28(38(36-25)27-13-11-26(12-14-27)37-18-16-35-17-19-37)23-4-2-21(3-5-23)22-6-8-24(9-7-22)30(31,32)33/h2-9,11-14,20,35H,10,15-19H2,1H3,(H,34,39)
• InChIKey: GHBUPSVATJKTRR-UHFFFAOYSA-N
• SMILES: CNC(=O)CCC1=NN(C(=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C4=CC=C(C=C4)N5CCNCC5

ILK-IN-1（Cat No.:I001269）is a small molecule inhibitor targeting integrin-linked kinase (ILK), a key protein involved in cell signaling, adhesion, and survival. ILK plays a crucial role in regulating the actin cytoskeleton, cell-matrix interactions, and signaling pathways that are implicated in cancer metastasis, angiogenesis, and fibrosis. By inhibiting ILK activity, ILK-IN-1 has shown potential in preclinical studies for suppressing tumor growth and metastasis, as well as mitigating fibrosis in various tissues. Ongoing research aims to further evaluate ILK-IN-1’s therapeutic potential, safety, and efficacy, particularly in cancer and fibrotic diseases.

Reference

[1]. Lee SL, et al. Identification and characterization of a novel integrin-linked kinase inhibitor. J Med Chem. 2011 Sep 22;54(18):6364-6374.